Arrowhead Pharmaceuticals Inc (ARWR) 73.33 USD (-0.01%)

Arrowhead Pharmaceuticals focuses on the development of drugs using RNA interference technology to treat genetic diseases.

biotechnology

Price history of Arrowhead Pharmaceuticals Inc

Performance & Momentum

6 Months 21.71 %

1 Year 354.31 %

3 Years 113.66 %

5 Years 15.70 %

Momentum

Unlock this indicator

Strategic Analysis

Arrowhead Pharmaceuticals Inc • 2026

Arrowhead Pharmaceuticals is positioned as a specialty biopharmaceutical company focused on RNA interference, with a platform approach designed to address hard-to-treat diseases. Its equity appeal rests on a portfolio of innovative therapies with strong potential, but also on a valuation that is highly sensitive to the clinical and regulatory progress of its programs.

Strengths

Recognized expertise in RNAi, a differentiated technological edge in biotechnology
High value-creation potential thanks to a platform capable of generating multiple therapeutic candidates
Very favorable stock momentum, reflecting a renewed wave of market confidence

Weaknesses

Heavy dependence on clinical results and regulatory milestones, with high binary risk
Historically volatile profile, typical of a development-stage biotech still exposed to execution uncertainty

Momentum

Momentum is very strong and part of a clearly upward trend, signaling a marked resurgence of investor interest in the story. Strategically, this places the stock in a favorable phase, but the strength of the equity momentum requires close attention to any clinical disappointment or shift in sentiment toward biotech risk.

Analysis performed yesterday